Sanofi-aventis reports positive Lantus trial data

Sanofi-aventis has published new clinical trial data which underlines the benefits delivered by its type 2 diabetes drug Lantus.

According to information reported at the European Association for the Study of Diabetes 46th Annual Meeting, the drug is able to deliver a greater reduction in blood sugar levels when added to oral antidiabetic drug therapy than all comparators, including OADs, NPH, lispro or premix.

In addition, further study data showed that Lantus is also able to deliver significant reduction of A1C levels in patients, independent of the baseline treatment regimen.

Dr Jack Leahy of the University of Vermont College of Medicine, principal investigator of one of the studies, assisted in the presentation of the results, saying they demonstrated the efficacy of Lantus compared to other oral antidiabetic drugs.

This comes after the firm published phase III data earlier this week on the type 2 diabetes drug lixisenatide, demonstrating its ability to deliver improvements in glycaemic control with a pronounced postprandial effect.